Long Term Safety of Infliximab
Infliximab is a chimeric anti-tumour necrosis factor-alpha monoclonal antibody that has been studied for the treatment of Crohn’s disease and rheumatoid arthritis. In several placebo controlled, randomized clinical trials and open trials, 771 patients have been given infliximab (a further 192 receiv...
Saved in:
Main Author: | Thomas F Schaible |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2000-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2000/698523 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Safety of Infliximab Infusions in the Community Setting
by: James Ducharme, et al.
Published: (2010-01-01) -
Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up
by: Jácome Bruges-Armas, et al.
Published: (2014-01-01) -
Response of Fibroblastic Rheumatism to Infliximab
by: Ricardo Romiti, et al.
Published: (2009-01-01) -
All That Bleeds Is Not Infliximab-Refractory Ulcerative Colitis
by: JK Law, et al.
Published: (2009-01-01) -
Crohn's Disease Associated with Sweet's Syndrome and Sjögren's Syndrome Treated with Infliximab
by: Erina N. Foster, et al.
Published: (2005-01-01)